<DOC>
	<DOCNO>NCT01016665</DOCNO>
	<brief_summary>Background : Identification new biomarkers potential predictive prognostic role contribute unequivocally breast cancer treatment . Although traditionally endocrine therapy base hormonal receptor status ( estrogen - ER progesterone- PR ) , patient become hormone resistant . In order identify possible profile associate hormonal resistance , biomarkers assess short period primary hormone therapy ( HT ) . Objectives : To compare expression Ki-67 , Bcl2 , Bax , Bak , ER e PR postmenopausal woman ER positive invasive ductal carcinoma ( IDC ) , prior tamoxifen anastrozole short term hormone therapy .</brief_summary>
	<brief_title>Anastrozole Reduced Proliferation Progesterone Receptor Indexes Short Term Hormone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Invasive breast cancer postmenopausal woman Estrogen and/or progesterone receptor positive Patients endocrine disease Hormone therapy user pregnant last 12 month diagnosis Patients negative expression estrogen and/or progesterone receptor Women history thromboembolism Patients previously undergone treatment breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Short Term</keyword>
	<keyword>Homontherapy</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>Short term hormonetherapy breast cancer</keyword>
</DOC>